Yale School of Public Health epidemiologist professor Harvey Risch again assured that hydroxychloroquine treatment is highly effective in helping people in the early stages of the CCP (Chinese Communist Party), especially those most at risk.
Amid the CCP Virus pandemic, Risch published in the Washington Examiner, said that hydroxychloroquine combined with zinc and appropriate antibiotics is amazingly effective in high-risk patients in recovering from the effects of the virus.
Risch made a distinction between the two stages of the disease, noting that while the treatment is likely to work quickly during the first stage, it is not effective in helping people who have advanced to the more severe second stage.
“The first thing to understand is that COVID-19 [the CCP Virus] has two main stages. At the first stage, it is a flu-like illness. That illness will not kill you. If you are a high-risk patient and begin treatment immediately, you will almost certainly be done with it in a few days.” Risch wrote, adding, “When not treated, high-risk patients may progress. The virus then causes severe pneumonia and attacks many organs, including the heart. In this second stage, hydroxychloroquine is not effective.”
Risch said that people in the high-risk category should be treated even before they receive their coronavirus test results. That is, he recommends it even as preventive treatment.
“The second thing to know is that most low-risk patients survive without treatment. Low risk means you are under age 60 and have no chronic conditions such as diabetes, obesity, and hypertension, have no past treatment for cancer, are not immunocompromised, etc. High risk means you are over 60 or you have one or more of those chronic conditions. High-risk patients need immediate treatment when they first show symptoms,“ the expert said.
Risch also took another strong stand at the FDA, which approved the emergency use of hydroxychloroquine for inpatients, while blocking requests for outpatient use. This is exactly the opposite of what Risch is proposing, according to the studies conducted.
As to why the FDA denied hydroxychloroquine, Risch wrote, “I can only speculate about the cause of the FDA’s recalcitrance. Hydroxychloroquine is an inexpensive, generic medication. Unlike certain profit-generating, patented medications, which have been promiscuously touted on the slimmest of evidence, hydroxychloroquine has no natural financial constituency. No one will get rich from it.”
In another article written by the epidemiologist in NewsWeek magazine, he also mentioned two other reasons why, despite the positive results demonstrated, hydroxychloroquine is not currently being used massively.
First, he argues, that the drug has become highly politicized. Many see it as identifying with one or the other political party. This is a real mistake. Medicine must be judged strictly according to science and politics should not intervene.
Secondly, he continued in his explanation, the drug has not been used correctly in many studies. Hydroxychloroquine has shown great success when used early in high-risk people, but, as you would expect from an antiviral, much less success when used late in the course of treatment.